Your search returned 3 results.

Results
	1.	Nivolumab or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer (TNBC) with residual disease following neoadjuvant chemotherapy: the OXEL study. MedStar authors: Dilawari, Asma Gallagher, Christopher Khoury, Katia Lynce, Filipa Swain, Sandra M Year: 2018 Department: MedStar Georgetown University Hospital Residents Form of publication: Conference All authors: Khoury K, Isaacs C, Gatti-Mays M, Donahue R, Schlom J, Wang H, Gallagher C, Graham D, Warren R, Dilawari A, Swain S, Pohlmann P, Lynce F. Local accession number: C2019_426 Add to cart (remove)
	2.	Molecular characterization of trophoblast cell surface antigen 2 (Trop-2) positive triple-negative breast cancer (TNBC). MedStar authors: Khoury, Katia Lynce, Filipa Swain, Sandra M Year: 2019 Citation: 2019/04/30/ Department: MedStar Georgetown University Hospital Residents Form of publication: Poster Presentation All authors: Khoury K, Feldman R, Pohlmann P, Lutterman A...[Swain S, Lynce F], et al. Local accession number: C2019_354 Add to cart (remove)
	3.	Nivolumab or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer (TNBC) with residual disease following neoadjuvant chemotherapy: the OXEL study. MedStar authors: Dilawari, Asma Gallagher, Christopher Khoury, Katia Lynce, Filipa Swain, Sandra M Year: 2019 Citation: 2019/04/30/ Department: MedStar Georgetown University Hospital Residents Form of publication: Poster Presentation All authors: Khoury K, Isaacs C, Gatti-Mays M, Donahue R, Schlom J, Wang H, Gallagher C, Graham D, Warren R, Dilawari A, Swain S, Pohlmann P, Lynce F. Local accession number: C2019_353 Add to cart (remove)

Powered by Koha